Wednesday, February 10, 2010, 8:16AM AEST - The Australian Stockmarket opens in 1 hour and 44 minutes.
To create a watchlist or portfolio of shares, Register

Helicos BioSciences Corporation (HLCS)

7:59AM AEST: 1.00 USD  Down 0.01 (0.99%)  
 MORE ON HLCS 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 Helicos BioSciences Corporation (NGM:HLCS) Delayed quote dataEdit
Last Trade:1.00 USD
Trade Time: 7:59AM AEST
Change:Down 0.01 (0.99%)
Prev Close:1.01
Open:0.99
Bid:0.99 x 300
Ask:1.02 x 1200
1y Target Est:2.00
Day's Range:1.00 - 1.01
52wk Range:0.38 - 3.54
Volume:243,208
Avg Vol (3m):1,245,500
Market Cap:72.96M
P/E (ttm):N/A
EPS (ttm):-0.56
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y 
 Add HLCS to Portfolio   Download Data

 HEADLINES 
Helicos Announces Additional System Installations for the St. Laurent Institute and Stanford University
Business Wire (Thu, Feb 4)
Gene Machine Wars Get Ever Hotter
at Forbes.com (Fri, Jan 29)
Helicos Introduces New Sequencing Kits to Enhance Versatility of the HeliScope Single Molecule Sequencer
Business Wire (Tue, Jan 26)
Biotech Stock Alert for Helicos BioSciences Corp. Issued by StockPreacher
GlobeNewswire (Thu, Jan 21)
Ballard Power, Enterra: Early Volume Plays
at TheStreet.com (Wed, Jan 20)
Helicos BioSciences Announces the Sale of a HelicosĀ® Genetic Analysis System to the Turku Centre for Biotechnology
Business Wire (Tue, Jan 19)
New Illumina Genome Sequencer Dramatically Slashes Costs, Time
at Seeking Alpha (Tue, Jan 19)
Illumina Unveils System to Cut Genome Sequencing Costs
at The Wall Street Journal Online (Wed, Jan 13)
Illumina's Cheap New Gene Machine
at Forbes.com (Wed, Jan 13)
Life Science Stocks: A Growing Market in 2010
at BusinessWeek (Tue, Dec 29)
HELICOS BIOSCIENCES CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Fi
EDGAR Online (Fri, Dec 18)
More Headlines for HLCS...

 ANALYST 
EPS Est (next year) (Dec-09) :-0.28
EPS Est (in 2 years) (Dec-10) :-0.09
Avg Rec (current)*:3.0
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Helicos BioSciences Corporation, a life sciences company, focuses on genetic analysis technologies for the research, drug discovery, and clinical diagnostics markets.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News7 Indices